SG11201906890TA - Oral thyroid therapeutic agent - Google Patents
Oral thyroid therapeutic agentInfo
- Publication number
- SG11201906890TA SG11201906890TA SG11201906890TA SG11201906890TA SG11201906890TA SG 11201906890T A SG11201906890T A SG 11201906890TA SG 11201906890T A SG11201906890T A SG 11201906890TA SG 11201906890T A SG11201906890T A SG 11201906890TA SG 11201906890T A SG11201906890T A SG 11201906890TA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agent
- thyroid therapeutic
- oral thyroid
- oral
- agent
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 210000001685 thyroid gland Anatomy 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 235000006708 antioxidants Nutrition 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 229950008325 levothyroxine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ORAL THYROID THERAPEUTIC AGENT The invention relates to an oral thyroid therapeutic agent, containing levothy- roxine or its pharmaceutically compatible salts as active agents, in combina- tion with at least one anti-oxidant and at least one absorption agent, wherein the weight percentage of active agents: anti-oxidants: adsorption agent is 1 : 1 : 5 - 1 : 50 : 100. FIGURE 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017102192 | 2017-02-03 | ||
| DE102017122807.1A DE102017122807B4 (en) | 2017-09-29 | 2017-09-29 | Oral thyroid therapeutic |
| PCT/EP2018/052713 WO2018141938A1 (en) | 2017-02-03 | 2018-02-02 | Oral thyroid therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906890TA true SG11201906890TA (en) | 2019-08-27 |
Family
ID=61256901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906890TA SG11201906890TA (en) | 2017-02-03 | 2018-02-02 | Oral thyroid therapeutic agent |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP3576795B1 (en) |
| CN (1) | CN110234356A (en) |
| CR (1) | CR20190352A (en) |
| CY (1) | CY1124264T1 (en) |
| DK (1) | DK3576795T3 (en) |
| DO (1) | DOP2019000199A (en) |
| ES (1) | ES2872249T3 (en) |
| GE (1) | GEP20217241B (en) |
| HR (1) | HRP20210799T1 (en) |
| HU (1) | HUE054988T2 (en) |
| LT (1) | LT3576795T (en) |
| MD (1) | MD3576795T2 (en) |
| NI (1) | NI201900083A (en) |
| PL (1) | PL3576795T3 (en) |
| PT (1) | PT3576795T (en) |
| RS (1) | RS61998B1 (en) |
| SG (1) | SG11201906890TA (en) |
| SI (1) | SI3576795T1 (en) |
| TW (1) | TWI753097B (en) |
| UA (1) | UA124642C2 (en) |
| WO (1) | WO2018141938A1 (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19541128C2 (en) * | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilized thyroid hormone-containing medicines |
| US6190591B1 (en) | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
| DE19830246A1 (en) | 1998-07-07 | 2000-01-13 | Merck Patent Gmbh | Pharmaceutical preparation |
| US20030099699A1 (en) | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| GB0316206D0 (en) * | 2003-07-10 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulation |
| US20090297566A1 (en) | 2004-12-27 | 2009-12-03 | Brinkman Kyle R | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions |
| CN101305099A (en) * | 2005-09-08 | 2008-11-12 | 夏尔有限责任公司 | Prodrugs of T3 and T4 with enhanced bioavailability |
| DE502005011092D1 (en) | 2005-10-05 | 2011-04-21 | Berlin Chemie Ag | Pharmaceutical protective packaging |
| GB0920041D0 (en) * | 2009-11-16 | 2009-12-30 | Univ Aston | Tablet |
| HUE035222T2 (en) * | 2012-08-20 | 2018-05-02 | Merck Patent Gmbh | Solid pharmaceutical preparation containing levothyroxine |
| US8779000B1 (en) | 2013-07-20 | 2014-07-15 | Nilesh Parikh | Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production |
-
2018
- 2018-02-02 PT PT187064225T patent/PT3576795T/en unknown
- 2018-02-02 SI SI201830290T patent/SI3576795T1/en unknown
- 2018-02-02 CN CN201880009870.1A patent/CN110234356A/en active Pending
- 2018-02-02 HU HUE18706422A patent/HUE054988T2/en unknown
- 2018-02-02 GE GEAP201815179A patent/GEP20217241B/en unknown
- 2018-02-02 DK DK18706422.5T patent/DK3576795T3/en active
- 2018-02-02 EP EP18706422.5A patent/EP3576795B1/en active Active
- 2018-02-02 WO PCT/EP2018/052713 patent/WO2018141938A1/en unknown
- 2018-02-02 UA UAA201909466A patent/UA124642C2/en unknown
- 2018-02-02 CR CR20190352A patent/CR20190352A/en unknown
- 2018-02-02 TW TW107103859A patent/TWI753097B/en active
- 2018-02-02 LT LTEP18706422.5T patent/LT3576795T/en unknown
- 2018-02-02 MD MDE20191355T patent/MD3576795T2/en unknown
- 2018-02-02 RS RS20210713A patent/RS61998B1/en unknown
- 2018-02-02 SG SG11201906890TA patent/SG11201906890TA/en unknown
- 2018-02-02 PL PL18706422T patent/PL3576795T3/en unknown
- 2018-02-02 ES ES18706422T patent/ES2872249T3/en active Active
-
2019
- 2019-07-31 DO DO2019000199A patent/DOP2019000199A/en unknown
- 2019-07-31 NI NI201900083A patent/NI201900083A/en unknown
-
2021
- 2021-05-18 HR HRP20210799TT patent/HRP20210799T1/en unknown
- 2021-06-17 CY CY20211100541T patent/CY1124264T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018141938A1 (en) | 2018-08-09 |
| CY1124264T1 (en) | 2022-07-22 |
| PT3576795T (en) | 2021-06-22 |
| CR20190352A (en) | 2019-10-25 |
| MD3576795T2 (en) | 2021-08-31 |
| LT3576795T (en) | 2021-07-26 |
| CN110234356A (en) | 2019-09-13 |
| EP3576795A1 (en) | 2019-12-11 |
| HUE054988T2 (en) | 2021-10-28 |
| DK3576795T3 (en) | 2021-06-07 |
| TW201836598A (en) | 2018-10-16 |
| DOP2019000199A (en) | 2019-10-31 |
| NI201900083A (en) | 2019-10-21 |
| HRP20210799T1 (en) | 2021-06-25 |
| SI3576795T1 (en) | 2021-07-30 |
| EP3576795B1 (en) | 2021-04-07 |
| ES2872249T3 (en) | 2021-11-02 |
| GEP20217241B (en) | 2021-04-12 |
| UA124642C2 (en) | 2021-10-20 |
| PL3576795T3 (en) | 2021-10-25 |
| TWI753097B (en) | 2022-01-21 |
| RS61998B1 (en) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201902429PA (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| BR112018069251A2 (en) | early intervention methods to prevent or improve toxicity | |
| BR112015023922A2 (en) | pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of using these | |
| NZ712270A (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| TR201904455T4 (en) | 1,2,4-triazoles and their uses as nuclear transport modulators. | |
| PE20142314A1 (en) | INTRANASAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM | |
| BR112012020731A2 (en) | soft gelatin tablets with nicotine. | |
| PH12015502542A1 (en) | Stabilized pemetrexed formulation | |
| MX2015013845A (en) | Tiotropium dry powders. | |
| AR082155A1 (en) | ANTISEPTIC AND DISINFECTANT FORMULATION THAT HAS REDUCED IODINE CONTENT | |
| BR112018014661A2 (en) | composition and composition for use | |
| AU2016216741A1 (en) | Compositions and methods of use of an inappetance-controlling compound | |
| MX2015000398A (en) | Laquinimod formulations without alkalizing agent. | |
| MX2022007391A (en) | Compounds active towards nuclear receptors. | |
| PH12015500610A1 (en) | Oral care composition | |
| PH12019500690A1 (en) | Oral care composition | |
| MX2022007265A (en) | Compounds active towards nuclear receptors. | |
| SG11201906890TA (en) | Oral thyroid therapeutic agent | |
| MX360844B (en) | Antiperspirant/deodorant composition. | |
| UA109944U (en) | PHARMACEUTICAL COMPOSITION TO REDUCE THE N-OXIDE OF TRIMETHYLAMINE LEVEL | |
| PH12018502339A1 (en) | Oral care composition | |
| AR110957A1 (en) | ORAL THERAPEUTIC AGENT FOR THYROID | |
| EA201900368A1 (en) | ORAL MEDICINE FOR THE THYROID GLAND | |
| EA201591994A1 (en) | CYSTEIN OR ITS DERIVATIVE FOR THE TREATMENT OF ATROPHIC GASTRITIS | |
| MX2022012259A (en) | Compounds active towards nuclear receptors. |